RBC Capital analyst Shagun Singh raised the firm’s price target on Insulet (PODD) to $330 from $325 and keeps an Outperform rating on the shares. The company delivered record Q1 sales with worldwide growth of about 30%, and its 2025 guide is still notably conservative, positioning Insulet for upside, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $330 from $310 at BTIG
- Insulet’s Strong Growth and Strategic Expansion Under New Leadership
- Insulet’s Strong Financial Performance and Growth Potential Drive Buy Rating
- Insulet’s Strong Financial Performance and Promising Future: A Buy Recommendation by Josh Jennings
- Insulet Corporation Reports Strong Q1 2025 Growth